This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Paraneoplastic neuromyopathy and neuropathy신생물딸림 신경근육병증 및 신경병증

Contents and key points
ItemDetails
A. Classification codesICD-10: G13.0 | Special Copayment Reduction: V287 (severe intractable disease, 5 years)
B. SynonymsParaneoplastic neuromyopathy, paraneoplastic neuropathy, paraneoplastic neurological syndrome (PNS)
C. Adult onsetLikelihood of adult onset: very high - autoimmune nervous system damage associated with an underlying malignancy (lung cancer, ovarian cancer, breast cancer, etc.), arising mainly in middle-aged to older adults (50s-70s). Neurologic symptoms may appear before or at the same time as tumor diagnosis.
1. History1960s: first description of paraneoplastic cerebellar degeneration → 1980s-90s: discovery of anti-Hu and anti-Yo antibodies → rapid expansion of antibodies after anti-NMDAR → 2020s: new antibodies continue to be discovered
2. CausesMalignancy (small cell lung cancer, ovarian cancer, breast cancer, lymphoma, etc.) → autoimmune response to tumor-expressed neural antigens → antineuronal autoantibodies (anti-Hu/ANNA-1, anti-CV2, anti-amphiphysin, etc.)
3. GeneticsNot directly hereditary; HLA background (HLA-DRB1, etc.) contributes to vulnerability to autoantibody formation; somatic mutations in the underlying tumor trigger the immune response
4. General epidemiologyRare disease; neurologic paraneoplastic syndrome occurs in about 3-5% of small cell lung cancer (SCLC) patients; annual incidence about 1-2 per million
5. PathophysiologyEctopic expression of tumor neural antigens (Hu, Yo, CV2, amphiphysin, etc.) → T-cell and B-cell activation → antibodies and CTLs cross-attack peripheral and central nerve cells
6. SymptomsSubacute sensory neuropathy (sensory loss, pain, gait disturbance), myopathy (muscle weakness, muscle atrophy), autonomic neuropathy (orthostatic hypotension, gastroparesis, bowel dysmotility), and cerebellar degeneration symptoms may accompany
7. SignsDecreased or absent deep tendon reflexes, sensory deficits (especially loss of vibration and position sense), decreased muscle strength, abnormal nerve conduction studies (axonal or demyelinating pattern), abnormal EMG, positive serum antineuronal antibodies
8. ScreeningAntineuronal autoantibody panel testing in patients with neuropathy or myopathy of unknown cause; search for malignancy (CT, PET-CT) when new neuropathy or myopathy appears
9. DiagnosisSerum and cerebrospinal fluid antineuronal antibodies (anti-Hu, anti-Yo, anti-CV2, anti-amphiphysin, etc.); nerve conduction studies and EMG; muscle and nerve biopsy; tumor search by PET-CT; clinical criteria (Graus 2016)
10. TreatmentTreatment of the underlying tumor (chemotherapy, radiation, surgery) is most important for stabilizing neurologic symptoms; immunotherapy (steroids, IVIG, plasma exchange, rituximab, cyclophosphamide)
11. PrognosisPrognosis varies with antibody type and tumor type; sensory neuropathy with anti-Hu antibody progresses poorly; some neurologic symptoms may improve with complete tumor remission; intracellular antibodies (anti-Hu, anti-Yo) have a limited response to immunotherapy
12. PreventionPrimary prevention is not possible; regular screening for early detection of malignancy; early tumor search when neurologic symptoms appear for early cancer treatment

1. History

Clinical recognition of paraneoplastic neurological syndromes (PNS) began in the late 19th century. In 1888, Auche first observed that peripheral neuropathy occurs in patients with malignancy, but it took decades for this to be recognized as an independent clinical entity.

Systematic understanding began in 1948 when Denny-Brown described subacute sensory neuropathy in lung cancer patients as an independent paraneoplastic syndrome. In the same period, paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome (LEMS) were recognized as neurologic complications associated with malignancy.

The decisive turning point came in 1985 when Graus et al. and Posner et al. first identified the anti-Hu antibody (ANNA-1, anti-neuronal nuclear antibody-1) in small cell lung cancer patients. This suggested that malignancy induces the production of specific antineuronal autoantibodies and that these antibodies are direct mediators of neural injury. The anti-Yo antibody (associated with ovarian and breast cancer in paraneoplastic cerebellar degeneration) was identified in 1988, and numerous antineuronal antibodies, including anti-Ri, anti-CV2/CRMP5, and anti-amphiphysin, were subsequently discovered one after another.

Since the 2000s, antibodies against cell surface antigens have been discovered rapidly. With the discovery of the anti-NMDAR encephalitis antibody in 2007, the boundary between encephalitis and paraneoplastic syndromes expanded. In 2016, Graus et al. revised the PNS diagnostic criteria, establishing the current clinical diagnostic system. The recent 2021 revision added new antibodies and refined the "definite," "probable," and "possible" classification criteria.


2. Causes

The fundamental cause of paraneoplastic neuromyopathy lies in malignancy. When tumor cells ectopically express proteins normally expressed only in nervous tissue, the immune system recognizes them as foreign antigens and mounts an autoimmune response. This response attacks not only tumor cells but also normal nervous tissue, causing neural injury.

Associated tumors

Small cell lung cancer (SCLC) is the most common causative tumor. SCLC, which has neuroendocrine features, ectopically expresses many neural proteins such as Hu, CV2, and amphiphysin. Ovarian cancer, particularly ovarian teratoma (associated with NMDAR antibody) and epithelial ovarian cancer (associated with Yo antibody), is an important cause. Breast cancer is associated with anti-amphiphysin and anti-Yo antibodies and can cause paraneoplastic cerebellar degeneration and sensory neuropathy. Thymoma is a cause of Lambert-Eaton syndrome and neuromyopathy. Lymphoma (Hodgkin and non-Hodgkin) can cause cerebellar degeneration associated with anti-Tr/DNER antibody.

Associations by antibody type

Antibodies against intracellular antigens (anti-Hu, anti-Yo, anti-CV2, anti-amphiphysin, anti-Ri, etc.) have strong specific tumor associations and a cytotoxic T-cell-mediated mechanism as the main pathology, with limited response to immunotherapy. Antibodies against cell surface antigens (anti-CASPR2, anti-LGI1, anti-VGCC, etc.) have variable tumor associations and direct antibody-mediated injury as the main mechanism, with a relatively good response to immunotherapy.


3. Genetics

Paraneoplastic neuromyopathy is not a directly inherited single-gene disease. However, an individual's immunogenetic background influences the occurrence and severity of tumor-related autoimmune responses. HLA genotype is associated with vulnerability to autoantibody formation. Specific HLA class II molecules (HLA-DRB1, HLA-DQB1) may efficiently present tumor antigen peptides to CD4+ T cells and promote the autoimmune response. In patients with paraneoplastic cerebellar degeneration associated with anti-Yo antibody, overrepresentation of the HLA-DRB1*03 allele has been reported.

Tumor mutational burden (TMB) of the underlying tumor and neoantigen generation may also influence the intensity of the paraneoplastic immune response. When immune checkpoint inhibitors (ICIs) are given, ICI-related paraneoplastic-like neurotoxicity can occur, which results from immune overactivation due to blockade of the PD-1/PD-L1 pathway.

In LEMS (Lambert-Eaton myasthenic syndrome), autoantibodies against voltage-gated calcium channels (VGCC) are formed. About 50% of LEMS is associated with SCLC, and the remainder is autoimmune LEMS associated with HLA-B8, DR3, and DQ2. In myasthenia gravis (MG), associations of AChR antibody with HLA-B8 and DR3 have been confirmed.


4. General epidemiology

Paraneoplastic neuromyopathy is a rare disease. It occurs in about 0.1-0.5% of all cancer patients, with an annual incidence estimated at about 1-2 per million. Neurologic paraneoplastic syndrome occurs in about 3-5% of small cell lung cancer (SCLC) patients. Epidemiology by specific antibody type: anti-Hu (ANNA-1)-associated syndrome is the most common paraneoplastic antibody, detected in about 16% of SCLC patients, though only some of them show clinical symptoms. Anti-Yo-associated paraneoplastic cerebellar degeneration occurs mainly in women with ovarian and breast cancer, showing a female predominance.

By sex, anti-Hu syndrome is slightly more common in men (SCLC-related), and anti-Yo syndrome occurs in women (ovarian and breast cancer-related). By age, it occurs mainly in middle to old age (50s-70s). In typical PNS (meeting probable PNS criteria), neurologic symptoms appear before the malignancy is identified in about 80%. This suggests that PNS offers an opportunity for early detection of the tumor. Epidemiologic data in Korea are limited, but occurrence of PNS should be actively monitored in patient groups with a high prevalence of lung, ovarian, and breast cancer.


5. Pathophysiology

The pathophysiology of paraneoplastic neuromyopathy is an autoimmune response against neural antigens ectopically expressed by tumor cells. This process consists broadly of the stages of ectopic expression of tumor antigens, immune activation, and attack on nervous tissue.

Ectopic expression of tumor antigens

Proteins normally expressed only in the brain and nervous system, which are immune-privileged sites (Hu, Yo, CV2, etc.), are ectopically expressed in malignant tumor cells. These proteins have important functions in the nervous system, such as RNA binding and regulation of cell survival and differentiation. Ectopic expression in tumor cells is exposed to the immune system through lymph nodes and so on, triggering an immune response.

Activation of the autoimmune response

Intracellular antigens (anti-Hu, anti-Yo, etc.): dendritic cells bind tumor antigen peptides to MHC class I and II molecules and activate CD8+ cytotoxic T cells (CTLs) and CD4+ helper T cells. Activated CTLs cross the blood-brain barrier and directly destroy nerve cells in the brain and spinal cord. Autoantibodies are also produced, but intracellular antigens are inaccessible in living cells, so the direct pathologic role of the antibodies themselves is limited.

Cell surface antigens (anti-VGCC, anti-CASPR2, etc.): IgG antibodies bind directly to the nerve cell surface through the blood and impair neural function by blocking channel or receptor function, through complement activation, or through receptor internalization. This mechanism responds better to immunotherapy.


6. Symptoms

The clinical symptoms of paraneoplastic neuromyopathy vary depending on the neural structures involved and the type of autoantibody. Most progress subacutely (weeks to months), and at the time of symptom onset the underlying malignancy is often not yet diagnosed.

Sensory neuropathy

Most strongly associated with the anti-Hu antibody. Symmetric or asymmetric sensory loss in the limbs (pain, numbness, burning sensation), preferential loss of deep sensation (position sense, vibration sense), sensory ataxia (gait disturbance), and autonomic dysfunction accompany it. Pain is severe at first, and functional decline progresses rapidly.

Myopathy and neuromuscular junction disorders

Paraneoplastic myopathy presents with proximal muscle weakness, myalgia, and muscle atrophy. Lambert-Eaton myasthenic syndrome (LEMS) is characterized by proximal lower-limb muscle weakness, autonomic abnormalities (dry mouth, erectile dysfunction), and an increase in muscle strength with repeated stimulation (facilitation). Myasthenia gravis (MG) is characterized by ocular and oropharyngeal muscle weakness and fatigability.

Autonomic neuropathy

Orthostatic hypotension, abnormal heart rate regulation, decreased gastrointestinal motility (gastroparesis, pseudo-obstruction), bladder dysfunction, and sweating abnormalities occur. Acute autonomic neuropathy can present with severe constipation, abdominal pain, and paralysis of gastrointestinal function.


7. Signs

On neurologic physical examination, decreased or absent deep tendon reflexes (especially in sensory neuropathy), sensory deficits (abnormal pinprick, vibration, and position sense tests), and decreased muscle strength (proximal-predominant or distal-predominant) are found.

Nerve conduction studies (NCS) and electromyography (EMG) are central to diagnosis. In sensory neuropathy, reduced or absent sensory nerve action potential (SNAP) amplitude with relatively preserved motor nerves is characteristic. In LEMS, amplitude decreases with low-frequency repetitive stimulation, and a marked amplitude increase (100% or more, facilitation) appears with high-frequency (50 Hz) stimulation or after exercise. EMG shows spontaneous activity (fibrillation potentials, positive sharp waves) and reinnervation findings.

Antineuronal autoantibodies (anti-Hu, anti-Yo, anti-CV2, anti-amphiphysin, anti-VGCC, etc.) are confirmed positive in serum or cerebrospinal fluid. MRI changes in the brain and spinal cord may appear in specific paraneoplastic syndromes (cerebellar degeneration, encephalomyelitis). Cerebrospinal fluid examination may show elevated protein and lymphocyte-predominant pleocytosis.


8. Screening

In patients with neuropathy or myopathy of unknown cause, antineuronal autoantibody panel testing is performed to differentiate a paraneoplastic cause. Paraneoplastic causes should be actively suspected especially in subacutely progressive sensory neuropathy, cerebellar degeneration, encephalomyelitis, and LEMS. When neurologic symptoms newly appear in a patient diagnosed with malignancy, antibody testing is performed to exclude paraneoplastic syndrome. If antibodies are positive, a search for malignancy (CT of chest/abdomen/pelvis, PET-CT if necessary, breast ultrasound and mammography, testicular ultrasound, etc.) must be performed. Even if no tumor is found on the initial search, repeat follow-up searches at 3-6 month intervals are recommended.


9. Diagnosis

The 2016 (revised 2021) diagnostic criteria of Graus et al. are the current standard. These criteria integrate clinical symptoms, antibody findings, and tumor confirmation to classify PNS as "definite," "probable," or "possible."

Antineuronal autoantibody testing: Testing of both serum and cerebrospinal fluid is recommended. Antibodies against intracellular antigens (anti-Hu, anti-Yo, anti-Ri, anti-CV2, anti-amphiphysin, anti-Ma2, etc.) are confirmed by IIFA (indirect immunofluorescence assay) and line blot or ELISA. For antibodies against cell surface antigens (anti-VGCC, anti-CASPR2, anti-LGI1, etc.), the cell-based assay (CBA) is the standard. Nerve conduction studies and EMG: classify the type of neuropathy (axonal, demyelinating, neuromuscular junction disorder). Imaging studies: brain and spinal cord MRI and PET-CT (tumor search) are performed. Muscle and nerve biopsy: performed when necessary for histologic confirmation (inflammatory cell infiltration, axonal loss, etc.).


10. Treatment

Treatment of paraneoplastic neuromyopathy consists broadly of two pillars: treatment of the underlying tumor and immunotherapy.

Treatment of the underlying tumor

The most important treatment in paraneoplastic syndromes is to treat the underlying malignancy as quickly as possible. When complete or partial remission of the tumor is achieved, progression of neurologic symptoms may stabilize or partly improve. This includes chemotherapy (especially platinum-based combination chemotherapy for SCLC), radiation therapy, and surgical resection (ovarian teratoma, etc.). If paraneoplastic-like neurotoxicity occurs during use of an immune checkpoint inhibitor (ICI), discontinuation of the ICI is considered.

Immunotherapy

In syndromes associated with intracellular antibodies (anti-Hu, anti-Yo, etc.), the effect of immunotherapy is limited, but it can be tried in the early acute phase. First-line treatment: high-dose corticosteroids (methylprednisolone 1 g/day × 3-5 days, then tapered), intravenous immunoglobulin (IVIG) 2 g/kg × 2-5 days, and plasma exchange (plasmapheresis, PE) 5-7 sessions are used. Second-line treatment: rituximab (375 mg/m² once weekly × 4 doses), cyclophosphamide. Syndromes associated with cell surface antibodies (anti-VGCC antibody in LEMS, etc.) respond better to immunotherapy. In LEMS, 3,4-diaminopyridine (3,4-DAP, amifampridine) is effective for symptomatic treatment.


11. Prognosis

The prognosis of paraneoplastic neuromyopathy varies greatly with the antibody type, the treatability of the underlying tumor, and the degree of neural injury at diagnosis.

In syndromes associated with intracellular antibodies (anti-Hu, anti-Yo, etc.), neural injury is mostly irreversible, so the prognosis tends to be poor. Anti-Hu-associated subacute sensory neuropathy progresses rapidly, and recovery of neural function is limited even after tumor treatment. In syndromes associated with cell surface antibodies (anti-VGCC, etc.), the response to immunotherapy is better, so functional recovery is possible in more cases. The prognosis of LEMS depends greatly on the prognosis of the underlying tumor (SCLC), and improvement of neuromuscular function is possible when tumor treatment and immunotherapy are applied together. The earlier the underlying tumor is detected and treated, the more likely progression of neural injury can be prevented. Overall, in paraneoplastic neuromyopathy, the later the diagnosis, the more irreversibly the neurologic impairment progresses, so early suspicion and prompt diagnosis are important.


12. Prevention

Primary prevention of paraneoplastic neuromyopathy itself is not possible. However, early detection and treatment of the underlying malignancy can prevent the occurrence or progression of paraneoplastic syndrome by removing the tumor before or early in the onset of neurologic symptoms. Cancer screening recommendations: in high-risk groups (smoking history, family history, age, etc.), regularly perform lung cancer screening (low-dose CT), breast cancer screening (mammography), and gynecologic screening (CA-125, pelvic ultrasound). When new neurologic symptoms (unexplained sensory abnormalities, gait disturbance, muscle weakness, etc.) appear, differentiate a paraneoplastic cause early to detect a hidden tumor early. In patients receiving immune checkpoint inhibitors (ICIs), evaluate immediately when neurotoxic symptoms appear and treat before progression to severe neural injury.


13. References

  1. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135-1140. DOI: 10.1136/jnnp.2003.034447. PMID: 15258215.
  2. Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated Diagnostic Criteria for Paraneoplastic Neurological Syndromes. Neurol Neuroimmunol Neuroinflamm. 2021;8(4):e1014. DOI: 10.1212/NXI.0000000000001014. PMID: 34006622.
  3. Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis. 2007;2:22. DOI: 10.1186/1750-1172-2-22. PMID: 17480225.
  4. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7(4):327-340. DOI: 10.1016/S1474-4422(08)70060-7. PMID: 18339348.
  5. Titulaer MJ, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann N Y Acad Sci. 2008;1132:129-134. DOI: 10.1196/annals.1405.030. PMID: 18567862.
  6. Rosenfeld MR, Dalmau J. Current therapies for paraneoplastic neurologic syndromes. Curr Treat Options Neurol. 2011;13(1):100-112. DOI: 10.1007/s11940-010-0099-z. PMID: 21108031.
  7. Antoine JC, Camdessanché JP. Paraneoplastic neuropathies. Curr Opin Neurol. 2007;20(5):623-628. DOI: 10.1097/WCO.0b013e3282ef2077. PMID: 17885450.
  8. Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2019;16(9):535-548. DOI: 10.1038/s41571-019-0194-4. PMID: 30996302.
  9. Vogrig A, Gigli GL, Segati S, et al. Outcomes of patients with paraneoplastic neurological syndromes and anti-Hu antibodies. Eur J Neurol. 2019;26(10):1309-1315. DOI: 10.1111/ene.13993. PMID: 31020751.
  10. Oh SJ. Paraneoplastic vasculitis of the peripheral nervous system. Neurol Clin. 1997;15(4):849-863. DOI: 10.1016/s0733-8619(05)70351-2. PMID: 9367973.